News & Updates

Anifrolumab for SLE shows favourable benefit–risk profile in extension study
Anifrolumab for SLE shows favourable benefit–risk profile in extension study
22 Nov 2022

Patients with moderate-to-severe systemic lupus erythematosus (SLE) appear to fare well with anifrolumab, with a recent study showing that the drug has an acceptable long-term safety profile and helps maintain reductions in disease activity and glucocorticoid usage.

Anifrolumab for SLE shows favourable benefit–risk profile in extension study
22 Nov 2022
TB rates elevated after ART initiation in PLHIV
TB rates elevated after ART initiation in PLHIV
21 Nov 2022 byRoshini Claire Anthony

People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.

TB rates elevated after ART initiation in PLHIV
21 Nov 2022
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
21 Nov 2022 byStephen Padilla

In patients with solitary metastatic recurrences of prostate cancer, metastasis-directed therapy (MDT without androgen deprivation therapy (ADT) can lead to delayed initiation of systemic therapy, according to a study.

MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
21 Nov 2022